NOVARTIS AG (NVS)
Health Care · Pharmaceuticals · NYSE
Novartis is a leading global innovative medicines company developing high-efficacy therapies for complex diseases like multiple sclerosis and chronic spontaneous urticaria.
What NOVARTIS AG does
Novartis is a global pharmaceutical company focused on researching, developing, and manufacturing innovative medicines. The company operates through a dedicated pipeline of therapeutic areas including immunology, neuroscience, cardiovascular, and oncology, utilizing advanced technology platforms like oral BTK inhibitors.
Themes: neuroscience, immunology, multiple sclerosis, chronic spontaneous urticaria, drug development
Fundamentals
- Price$161.25 as of 2026-09-01 close
- Market cap$227.4B as of 2026-09-03
- 1-year return+27.4% 2025-08-29 close $126.55 → 2026-09-01 close $161.25
- P/E21.95 as of 2026-09-03
- ROE+30.0% FY2025, SEC XBRL
- Debt / equity1.18 as of 2026-09-03
- Revenue growth (YoY)+3.3% as of 2026-09-03
- Beta1.17 as of 2026-09-03
- Last reported earningsn/a no confirmed date — as a foreign private issuer it reports on Form 6-K, which carries no earnings item code
Dividend: yield +3.7%; pays a dividend.
How NVS compares in its sector
- price-to-earnings ratiomiddle range 197 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 507 covered Health Care peers, as of 2026-09-03
- indicated dividend yieldtop 25% 71 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NVS is not currently in any published Top 10 list. Its scores are below.
Long-term score
59.0 #312 of 1,587 scored · #36 of 197 in Health Care
Profitability 82nd (operating margin 29.9%, return on equity 29.9%) and long-term trend 76th (a "golden cross" — its 50-day average is above its 200-day); weakest is growth (26th, revenue growth year over year 3.3%). Scored on 5 of 6 pillars — it pays a dividend, but its filings carry no per-share series to count increases from; no annual share count in its filings.
Short-term score
58.8 #276 of 1,683 scored · #65 of 241 in Health Care
Volume and participation 94th: trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest; trend 76th: a "golden cross" — its 50-day average is above its 200-day; weakest is catalysts 34th: open-market insider buys in 90 days 0, analysts' average price target is unchanged from the prior reading. Its short interest was not measured, so no short-interest deduction applies.
Scores as of 1 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, NVS's dividend was covered by reported results (earnings payout 56%, free-cash-flow payout 44%). This describes past coverage, not a forecast.
- Earnings payout56% dividends / net income
- Free-cash-flow payout44% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How NOVARTIS AG looks technically
NOVARTIS AG (NVS) is trading 8.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 353 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-03-10, pushing above its recent trading range. Trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest.
Trend
7
| Distance from the 200-day | it is trading 8.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $155.02 | $155.02 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $149.15 | $149.15 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 353 trading days ago — a "golden cross", a bullish long-term signal | 353 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 13.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 58.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($149.10 to $163.57) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 84.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $170.46 | $170.46 |
|---|---|---|
| From the 52-week high | it is 5.4% below its 52-week high (its highest price of the past year) | -5.4% |
| Above the 52-week low | it is 32.6% above its 52-week low (its lowest price of the past year) | +32.6% |
| Below the 52-week high | it is 5.4% below its highest point of the past year | 5.4% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-03-10, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-03-10, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $170.46 (set on 2026-02-27) | $170.46 |
| Given back of the 52-week move | over the past year its closes ranged ($121.80 to $168.62), and it has given back roughly a quarter of its rise from last year’s low — 16% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $138.19 to $139.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 15.7% |
| From the all-time high | it is 5.4% below its all-time high | -5.4% |
| Nearest price level | it is sitting right on a support level at $160.57 — a price it turned at three times since 2026-07-02, most recently on 2026-08-19. Since 2024-09-03 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.4% |
| All-time low | its lowest closing price on record is $23.24 (set on 1997-01-21) | $23.24 |
| Above the all-time low | it is 593.8% above its all-time low | +593.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 62nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.49 between its high and its low — about 2.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.49 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $149.54 and $161.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $149.54 – $155.53 – $161.51 |
| Typical daily range (% of price) | its price moves about 2.2% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.2% |
| Stretch from the 200-day average | it is trading 3.5 daily ranges above its 200-day average price (8.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest | 2.84× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-09-01 6.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +6.6% |
|---|---|---|
| Open gap | it gapped 6.6% above the previous close today and has not traded back through the level it left behind at 152.06 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.6% |
| Gap filled | a 3.9% gap up opened on 2026-07-21 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it took 17 sessions to close | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.3 percentage points (the stock gained 3.3% while the market gained 2.0%) | +1.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.3 percentage points (the stock gained 10.7% while the market gained 0.4%) | +10.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.4 percentage points (the stock lost 4.4% while the market gained 11.0%) | -15.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 9.3 percentage points (the stock gained 27.4% while the market gained 18.1%) | +9.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-27 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.6% of the share price, which is taken to mean a barrier that gives way easily. | +4.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $153.55 — a volume-weighted average of daily closes over 166 sessions, not a true tick-by-tick VWAP. | +5.0% |
|---|
Rectangle, either side — broke out · entry $160.34 · 41 sessions in
Double bottom, bullish — broke out · entry $159.85 · 30 sessions in
Price levels it has turned at before
NVS last closed at $161.25 on 2026-09-01. Since 2024-09-03 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $160.57 | Support | 0.4% below the last close | turned there three times · 2026-07-02 to 2026-08-19 |
| $156.90 | Support | 2.7% below the last close | turned there twice · 2026-04-10 to 2026-08-11 |
| $153.19 | Support | 5.0% below the last close | turned there four times · 2026-01-27 to 2026-08-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-09-01.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-09-01. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.83 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$157.15 range $123.00 – $180.00; median $160.15
Analyst estimates, as of 2026-08-30. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NVS
- Consensus EPS estimate$2.23 next reporting period, as of 2026-08-30
- Readings revised upward0% of 3 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure or negative results in late-stage drug development pipelines.","Regulatory hurdles for global drug approval processes and pricing pressures.","Risks associated with drug safety profiles and potential long-term adverse effects discovered post-approval."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2020-06-30. As of 2026-09-04.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NVS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
NVS had 4,993,689 shares of reported short interest as of the 2026-08-14 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for NVS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 4,993,689
- Prior settlement (shares) 5,240,722
- Reported change -4.71%
- Days to cover (reported) 3.43
Reported to FINRA as of the 2026-08-14 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (ROG.SW)
- Sanofi (SNY)
- Merck & Co. (MRK)
- Bristol Myers Squibb (BMY)
- AstraZeneca (AZN)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NVS vs…
NOVARTIS AG is found in…
Frequently asked questions
What does NOVARTIS AG (NVS) do?
Novartis is a global pharmaceutical company focused on researching, developing, and manufacturing innovative medicines. The company operates through a dedicated pipeline of therapeutic areas including immunology, neuroscience, cardiovascular, and oncology, utilizing advanced technology platforms like oral BTK inhibitors.
What sector is NOVARTIS AG (NVS) in?
NOVARTIS AG (NVS) is classified in the Health Care sector. Its industry is Pharmaceuticals. It trades on NYSE.
Does NVS pay a dividend?
Yes — NOVARTIS AG (NVS) pays a dividend, with an indicated yield of about 3.72% (market data, as of 2026-09-03). Informational only — not financial advice.
Who are NOVARTIS AG's (NVS) competitors?
Notable peers of NOVARTIS AG (NVS) include Roche, Sanofi, Merck & Co., Bristol Myers Squibb and AstraZeneca. This peer set is informational only — not financial advice.
Is NOVARTIS AG (NVS) overbought or oversold right now?
NOVARTIS AG (NVS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-09-01). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NVS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-01.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.